Most researchers seeking out CJC-1295 in Daraj rapidly learn that local retail options are virtually absent. The key implication for Daraj researchers: sourcing CJC-1295 depends entirely on vendor quality evaluation, not geography — and the evaluation methodology is the same regardless of where you are. What genuinely separates top CJC-1295 vendors is full COA coverage: HPLC for purity, mass spec for identity and weight verification, and endotoxin testing for contamination assurance. This guide walks Daraj researchers through that evaluation process and explains how to verify CJC-1295 vendor quality step by step.
Understanding CJC-1295 — Biology & Evidence
The selectivity profile of different GHS compounds is a critical research consideration. GHRP-6 and GHRP-2 produce GH release alongside cortisol and prolactin elevation — a confounding factor in research designs where these hormones are outcome variables. Ipamorelin was specifically developed for greater GH-release selectivity with minimal cortisol and prolactin elevation, making it more suitable for research designs where GH-specific effects need to be isolated. Hexarelin has the strongest GH-releasing potency in the GHRP class but also the most significant cortisol and prolactin effects. For Daraj researchers designing GH-axis studies, compound selection based on this selectivity profile should precede protocol finalization.
How to Evaluate CJC-1295 Vendors
Quality CJC-1295 sourcing begins with a straightforward question: does this vendor share complete COA data without being asked? Vendors who do are operating transparently. Endotoxin testing in the COA is essential for any injectable research use — endotoxins from bacterial cell wall components can trigger severe inflammatory responses even at trace quantities. Community reputation in research forums is a complementary signal to COA verification — vendors with sustained positive community feedback have built their reputation on real product performance. The powdered lyophilised form of CJC-1295 is far superior to liquid pre-made solutions — lyophilised powder stays viable for years at −20°C, while liquid preparations break down rapidly even under refrigeration.
Order CJC-1295 — ships to Daraj
COA-verified · International tracking · Research grade
As a research compound, CJC-1295 has not completed the clinical trial process required for pharmaceutical approval — its safety profile is characterised by preclinical data and limited human studies. Reconstitute CJC-1295 with bacteriostatic water at an appropriate concentration for your protocol; a standard 5mg reconstituted in 2mL produces 2.5mg/mL — or 25mcg per insulin syringe unit. Bacterial endotoxin contamination is the primary safety concern specific to research peptides — verify endotoxin testing is documented in your batch COA before any injectable research application. The research literature on CJC-1295 should be read critically before beginning any research — study designs, dosing ranges, and outcome measures vary significantly and conclusions do not uniformly extrapolate.
Frequently Asked Questions
What purity is required for CJC-1295 research?
CJC-1295 should be ≥98% pure by HPLC. The larger molecular weight of CJC-1295 with DAC (approximately 3647 Da) makes mass spectrometry confirmation particularly important, as impurities may not be obvious on HPLC alone.
What is the difference between CJC-1295 with DAC and without DAC?
CJC-1295 with DAC uses a lysine-maleimide conjugate to bind covalently to albumin in the bloodstream, extending half-life to ~6-8 days and creating sustained GH elevation. CJC-1295 without DAC (also called Mod GRF 1-29) has a half-life of ~30 minutes and produces acute GH pulses. They produce different GH secretion patterns and have different applications in research.
What is CJC-1295?
CJC-1295 is a synthetic GHRH (Growth Hormone Releasing Hormone) analogue. The version with DAC (Drug Affinity Complex) has an extended half-life of approximately 6-8 days due to albumin binding. Without DAC, CJC-1295 has a much shorter half-life similar to native GHRH. Both versions stimulate pulsatile GH release via the GHRH receptor.
